Cargando…

Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial

The impact of chemotherapy resistant B cells in multiple myeloma (MM) needs to be evaluated by in vivo targeted therapy. Here we report the conclusions from a phase II randomized, placebo controlled trial adding fludarabine to the induction with cyclophosphamide-dexamethasone. Based on an interim to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnsen, Hans E, Knudsen, Lene M., Mylin, Anne K, Gimsing, Peter, Gregersen, Henrik, Abildgaard, Niels, Andersen, Nils Frost, Plesner, Torben, Vangsted, Annette, Mourits-Andersen, Torben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications 2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222252/ http://dx.doi.org/10.4081/hr.2009.e11

Ejemplares similares

The Danish National Multiple Myeloma Registry
por: Gimsing, Peter, et al.
Publicado: (2016)

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
por: Schmitz, Alexander, et al.
Publicado: (2022)

Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis*
por: Lund, Thomas, et al.
Publicado: (2010)

The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population‐based study
por: Gregersen, Henrik, et al.
Publicado: (2017)

No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
por: Vangsted, Annette J, et al.
Publicado: (2010)

A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma
por: Gregersen, Henrik, et al.
Publicado: (2018)

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
por: Groen, Kazimierz, et al.
Publicado: (2023)

Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
por: Plesner, Torben
Publicado: (2021)

First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro
por: Lund, Thomas, et al.
Publicado: (2010)

Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration
por: Andersen, Hjalte Holm, et al.
Publicado: (2013)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial
por: Gimsing, P, et al.
Publicado: (2015)

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
por: Sørrig, Rasmus, et al.
Publicado: (2017)

P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13
por: Groen, K., et al.
Publicado: (2022)

Neurological illness following treatment with fludarabine.
por: Johnson, P. W., et al.
Publicado: (1994)

[(18)F]-Fludarabine for Hematological Malignancies
por: Barré, Louisa, et al.
Publicado: (2019)

Strategies to improve patient-reported outcome completion rates in longitudinal studies
por: Nielsen, Lene Kongsgaard, et al.
Publicado: (2019)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

Histiocytic Sarcoma: Challenging Course, Dismal Outcome
por: Andersen, Kim Francis, et al.
Publicado: (2021)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Andersen, Kristian T., et al.
Publicado: (2020)

A novel kinetic energy harvesting system for lifetime deployments of wildlife trackers
por: Gregersen, Troels, et al.
Publicado: (2023)

Association Testing of Novel Type 2 Diabetes Risk Alleles in the JAZF1, CDC123/CAMK1D, TSPAN8, THADA, ADAMTS9, and NOTCH2 Loci With Insulin Release, Insulin Sensitivity, and Obesity in a Population-Based Sample of 4,516 Glucose-Tolerant Middle-Aged Danes
por: Grarup, Niels, et al.
Publicado: (2008)

Maternal Multiple Sclerosis and Health Outcomes Among the Children: A Systematic Review
por: Andersen, Mette Louise, et al.
Publicado: (2023)

Integrated Modeling of Telescopes
por: Andersen, Torben, et al.
Publicado: (2011)

High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4(+) T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens
por: Iversen, Katrine Fladeland, et al.
Publicado: (2022)

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
por: Mikkelsen, Stine Ulrik, et al.
Publicado: (2018)

Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
por: Whelan, J. S., et al.
Publicado: (1991)

Fludarabine in the treatment of chronic lymphocytic leukemia: a review
por: Ricci, Francesca, et al.
Publicado: (2009)

Low-grade lymphoma: Beyond fludarabine-single therapy
por: Park, Eunkyung
Publicado: (2011)

Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia
por: Janssens, Ann, et al.
Publicado: (2009)

Fludarabine-induced bradycardia in a patient with refractory leukemia
por: Chung-Lo, Woei, et al.
Publicado: (2010)

Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
por: Zweegman, Sonja, et al.
Publicado: (2020)

The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study
por: Szabo, Agoston Gyula, et al.
Publicado: (2019)

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
por: Sørensen, Anders Lindholm, et al.
Publicado: (2020)

Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey
por: Armstrong, April, et al.
Publicado: (2022)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

Follow the leader? Orange-fronted conures eavesdrop on conspecific vocal performance and utilise it in social decisions
por: Thomsen, Heidi M., et al.
Publicado: (2021)

T-cell large granular lymphocytic leukemia: treatment experience with fludarabine
por: Costa, Renata Oliveira, et al.
Publicado: (2012)

MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
por: Ferracin, Manuela, et al.
Publicado: (2010)

Telomerase Contributes to Fludarabine Resistance in Primary Human Leukemic Lymphocytes
por: Shawi, May, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7ndjiva4pu3hf3o10mmnot0vd0